Lantheus Holdings, Inc
LNTHLantheus Holdings, Inc. is a global healthcare company specializing in diagnostic and therapeutic solutions for cardiovascular and other diseases. The company develops and markets agents used in medical imaging and treatment, including radio-injectable products that aid in the detection and management of various medical conditions. Founded in 1957, Lantheus is focused on advancing imaging technology to improve patient outcomes.
Company News
The metastatic prostate cancer market is projected to experience robust growth through 2036, valued at USD 11.5 billion in 2025 across seven major markets. The market is transitioning from conventional androgen deprivation therapy toward combination-based, biomarker-driven approaches, with novel therapies such as PSMA-targeted radioligand therapi...
The global radiopharmaceuticals market is projected to grow from USD 8.28 billion in 2026 to USD 15.21 billion by 2035, driven by rising cancer and cardiovascular disease incidence. North America dominates with 43.95% market share, while Asia-Pacific is expected to register the fastest growth. Therapeutic radiopharmaceuticals and Technetium-99m l...
Lantheus Holdings reported Q4 2025 revenue of $406.8 million and full-year revenue of $1.54 billion, with adjusted EPS of $1.67 and $6.08 respectively. The company announced a strategic refocus on PET radiodiagnostics and plans to pursue value-maximizing alternatives for radiotherapeutic assets. Despite PYLARIFY sales declining 9.7% in Q4, the co...
PYLARIFY has become the first blockbuster radiodiagnostic, exceeding $1 billion in 2024 net sales with 24.3% growth. PLUVICTO, a radioligand therapeutic agent, posted $1.392 billion in 2024 sales with 42% growth. PSMA-targeted therapies and radiodiagnostics represent a clinically validated and commercially successful approach for prostate cancer ...
Lantheus Holdings announced it will host an earnings conference call and webcast on February 26, 2026, at 8:00 a.m. ET to discuss its fourth quarter and full year 2025 financial and operating results. The company also recently closed the sale of its SPECT business to SHINE Technologies.
